SPECIFIC LONG-TERM OBJECTIVES ARE TO DEVELOP A DIAGNOSTIC TEST THAT WILL DETECT THE OCCURRENCE OF DIABETIC NEPHROPATHYAT AN EARLIER, TREATABLE PHASE.

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: N/A
Agency Tracking Number: 4891
Amount: $50,000.00
Phase: Phase I
Program: SBIR
Awards Year: 1986
Solitcitation Year: N/A
Solitcitation Topic Code: N/A
Solitcitation Number: N/A
Small Business Information
O'connor Diagnostics Corp
324 East Wisconsin Ave, Milwaukee, WI, 53202
Duns: N/A
Hubzone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 HOWARD SEAN O'CONNOR
 PRINCIPAL INVESTIGATOR
 (414) 272-2676
Business Contact
Phone: () -
Research Institution
N/A
Abstract
SPECIFIC LONG-TERM OBJECTIVES ARE TO DEVELOP A DIAGNOSTIC TEST THAT WILL DETECT THE OCCURRENCE OF DIABETIC NEPHROPATHYAT AN EARLIER, TREATABLE PHASE. THE DEVELOPED TEST REAGENT WILL BE MONOCLONAL ANTIBODIES TO ANTIGENS THAT ARE ASSOCIA- TED WITH DIABETIC NEPHROPATHY. THE SOURCE OF DIABETIC NEPHROTIC-RELATED ANTIGEN WILL BE CIRCULATING IMMUNE COMPLEXES THAT OCCUR IN THE BLOOD OF ALL HUMAN DIABETICS DEVELOPING THIS PROGRESSIVE KIDNEY DISEASE. PHASE I WILL INVOLVE ORGANIZATION AND COLLECTION OF ALL RESEARCH DATA TO BEGIN SCREENING OF HYBRIDOMAS FOR ANTIBODY PRODUCTION TO POTENTIAL MARKERS FOR HUMAN DIABETIC NEPHROPATHY. PHASE II WILL ENTAIL ANTIGEN CHARACTERIZATION, OCCURENCE, SPECIFICITY, AND RELATEDNESS TO OTHER DISEASES. AS DIABETICNEPHROPATHY AFFECTS HALF OF THE TYPE I DIABETICS, A SPECIFIC, RAPID, INEXPENSIVE TEST PERFORMED AT THE CLINICAL LEVEL HAS ENORMOUS MEDICAL IMPORTANCE FOR DIAGNOSING AND EVENTUALLY TREATING NEPHROPATHIC DIABETICS. PRESENTLY THE ONLY RELIABLE DIAGNOSTIC TEST IS PROTEINURIA WHICH, TRAGICALLY, DETECTS KIDNEY DISEASE AT AN IRREVERSIBLE STAGE.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government